OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy.

OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK.  The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel.  OncoSil™ is designated as a breakthrough device in both Europe and the United States¹.

We believe in our technology and its ability to have a truly positive impact in Oncology.

OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications.

Website link: oncosil.com

References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.


Health Care

Life Sciences

Medical Devices

OncoSil Medical

Nigel Lange

Antonio Ponce Cuesta

Renzo Dicarlo

Jon Bell

Christian Dal Cin

The Leadership Team at OncoSil Medical is responsible for steering the company towards its strategic goals in Interventional Oncology. This team oversees financial planning, corporate strategy, medical and clinical affairs, and global market expansion, ensuring the successful implementation and regulatory compliance of OncoSil™ products. Their primary aim is to enhance the company's impact in improving oncology treatment outcomes worldwide.

Leadership Team

Clinical and Medical Affairs

��

Leadership Team

About

Team members

Other teams at OncoSil Medical

Clinical and Medical Affairs

��������

Leadership Team

About

Team members

Other teams at OncoSil Medical

Clinical and Medical Affairs

��